A dose-escalation study of carboplatin/cyclophosphamide/ etoposide along with autologous bone marrow or peripheral blood stem cell rescue

Thomas C. Shea, Anna Maria Storniolo, James R. Mason, Barbara Newton, Michael Mullen, Raymond Taetle, Mark R. Green

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Twenty patients have received 21 courses of high-dose cyclophosphamide (6 g/m2 over 4 days), etoposide (1,800 mg/m2 over 3 days), and carboplatin (800 to 1,600 mg/m2 by continuous infusion over 96 hours) and autologous bone marrow or peripheral blood stem cell rescue. The maximum tolerated dose of this regimen included these doses of cyclophosphamide and etoposide with a total of 1,600 mg/m2 carboplatin. Acute renal failure was the dose-limiting toxicity and, at the maximum tolerated dose, was observed in two patients of 14 evaluable courses. Nonhematologic toxicity was otherwise modest, and the overall response rate was 70% in patients with a wide variety of solid and hematologic neoplasms.

Original languageEnglish (US)
Pages (from-to)139-144
Number of pages6
JournalSeminars in Oncology
Volume19
Issue number1 SUPPL. 2
StatePublished - 1992
Externally publishedYes

Fingerprint

Carboplatin
Etoposide
Cyclophosphamide
Maximum Tolerated Dose
Bone Marrow
Hematologic Neoplasms
Acute Kidney Injury
Peripheral Blood Stem Cells

ASJC Scopus subject areas

  • Oncology

Cite this

A dose-escalation study of carboplatin/cyclophosphamide/ etoposide along with autologous bone marrow or peripheral blood stem cell rescue. / Shea, Thomas C.; Storniolo, Anna Maria; Mason, James R.; Newton, Barbara; Mullen, Michael; Taetle, Raymond; Green, Mark R.

In: Seminars in Oncology, Vol. 19, No. 1 SUPPL. 2, 1992, p. 139-144.

Research output: Contribution to journalArticle

Shea, Thomas C. ; Storniolo, Anna Maria ; Mason, James R. ; Newton, Barbara ; Mullen, Michael ; Taetle, Raymond ; Green, Mark R. / A dose-escalation study of carboplatin/cyclophosphamide/ etoposide along with autologous bone marrow or peripheral blood stem cell rescue. In: Seminars in Oncology. 1992 ; Vol. 19, No. 1 SUPPL. 2. pp. 139-144.
@article{850b11601d1c47189d1fb65e212bfaee,
title = "A dose-escalation study of carboplatin/cyclophosphamide/ etoposide along with autologous bone marrow or peripheral blood stem cell rescue",
abstract = "Twenty patients have received 21 courses of high-dose cyclophosphamide (6 g/m2 over 4 days), etoposide (1,800 mg/m2 over 3 days), and carboplatin (800 to 1,600 mg/m2 by continuous infusion over 96 hours) and autologous bone marrow or peripheral blood stem cell rescue. The maximum tolerated dose of this regimen included these doses of cyclophosphamide and etoposide with a total of 1,600 mg/m2 carboplatin. Acute renal failure was the dose-limiting toxicity and, at the maximum tolerated dose, was observed in two patients of 14 evaluable courses. Nonhematologic toxicity was otherwise modest, and the overall response rate was 70{\%} in patients with a wide variety of solid and hematologic neoplasms.",
author = "Shea, {Thomas C.} and Storniolo, {Anna Maria} and Mason, {James R.} and Barbara Newton and Michael Mullen and Raymond Taetle and Green, {Mark R.}",
year = "1992",
language = "English (US)",
volume = "19",
pages = "139--144",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 SUPPL. 2",

}

TY - JOUR

T1 - A dose-escalation study of carboplatin/cyclophosphamide/ etoposide along with autologous bone marrow or peripheral blood stem cell rescue

AU - Shea, Thomas C.

AU - Storniolo, Anna Maria

AU - Mason, James R.

AU - Newton, Barbara

AU - Mullen, Michael

AU - Taetle, Raymond

AU - Green, Mark R.

PY - 1992

Y1 - 1992

N2 - Twenty patients have received 21 courses of high-dose cyclophosphamide (6 g/m2 over 4 days), etoposide (1,800 mg/m2 over 3 days), and carboplatin (800 to 1,600 mg/m2 by continuous infusion over 96 hours) and autologous bone marrow or peripheral blood stem cell rescue. The maximum tolerated dose of this regimen included these doses of cyclophosphamide and etoposide with a total of 1,600 mg/m2 carboplatin. Acute renal failure was the dose-limiting toxicity and, at the maximum tolerated dose, was observed in two patients of 14 evaluable courses. Nonhematologic toxicity was otherwise modest, and the overall response rate was 70% in patients with a wide variety of solid and hematologic neoplasms.

AB - Twenty patients have received 21 courses of high-dose cyclophosphamide (6 g/m2 over 4 days), etoposide (1,800 mg/m2 over 3 days), and carboplatin (800 to 1,600 mg/m2 by continuous infusion over 96 hours) and autologous bone marrow or peripheral blood stem cell rescue. The maximum tolerated dose of this regimen included these doses of cyclophosphamide and etoposide with a total of 1,600 mg/m2 carboplatin. Acute renal failure was the dose-limiting toxicity and, at the maximum tolerated dose, was observed in two patients of 14 evaluable courses. Nonhematologic toxicity was otherwise modest, and the overall response rate was 70% in patients with a wide variety of solid and hematologic neoplasms.

UR - http://www.scopus.com/inward/record.url?scp=0026820613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026820613&partnerID=8YFLogxK

M3 - Article

C2 - 1411625

AN - SCOPUS:0026820613

VL - 19

SP - 139

EP - 144

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 SUPPL. 2

ER -